BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28340404)

  • 21. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
    Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
    Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
    [No Abstract]   [Full Text] [Related]  

  • 23. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors.
    Celik İ; Ayhan-Kılcıgil G; Guven B; Kara Z; Gurkan-Alp AS; Karayel A; Onay-Besikci A
    Eur J Med Chem; 2019 Jul; 173():240-249. PubMed ID: 31009910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
    Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
    Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
    Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
    Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications.
    Zień P; Abramczyk O; Domańska K; Bretner M; Szyszka R
    Biochem Biophys Res Commun; 2003 Dec; 312(3):623-8. PubMed ID: 14680810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks.
    Schneider CC; Hessenauer A; Götz C; Montenarh M
    Oncol Rep; 2009 Jun; 21(6):1593-7. PubMed ID: 19424641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
    Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
    Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro.
    Schneider CC; Kartarius S; Montenarh M; Orzeszko A; Kazimierczuk Z
    Bioorg Med Chem; 2012 Jul; 20(14):4390-6. PubMed ID: 22698781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
    Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
    Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, docking and in vitro anticancer evaluation of some new benzopyrone derivatives.
    El-Ansary SL; Hussein MM; Abdel Rahman DE; Abdel Ghany LM
    Bioorg Chem; 2014 Apr; 53():50-66. PubMed ID: 24607350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues--inhibitors of the NTpase/helicase of HCV and of some related Flaviviridae.
    Bretner M; Baier A; Kopańska K; Najda A; Schoof A; Reinholz M; Lipniacki A; Piasek A; Kulikowski T; Borowski P
    Antivir Chem Chemother; 2005; 16(5):315-26. PubMed ID: 16245647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity.
    Zhang S; Luo Y; He LQ; Liu ZJ; Jiang AQ; Yang YH; Zhu HL
    Bioorg Med Chem; 2013 Jul; 21(13):3723-9. PubMed ID: 23673215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, in vitro and in vivo antitumor and antiviral activity of novel 1-substituted benzimidazole derivatives.
    Shaker YM; Omar MA; Mahmoud K; Elhallouty SM; El-Senousy WM; Ali MM; Mahmoud AE; Abdel-Halim AH; Soliman SM; El Diwani HI
    J Enzyme Inhib Med Chem; 2015; 30(5):826-45. PubMed ID: 25567722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2.
    Zien P; Duncan JS; Skierski J; Bretner M; Litchfield DW; Shugar D
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):271-80. PubMed ID: 16203192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.